Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2016.0051
• Publication Date: 2017-04-14T16:08:04Z
• Authors: Daniel G. Coit; John A. Thompson; Alain Algazi; Robert Andtbacka; Christopher K. Bi...; William E. Carson; Gregory A. Daniels; Dominick DiMaio; Marc Ernstoff; Ryan C. Fields; Martin D. Fleming; Rene Gonzalez; Valerie Guild; Allan C. Halpern; F. Stephen Hodi; Richard W. Joseph; Julie R. Lange; Mary C. Martini; Miguel A. Materin; Anthony J. Olszanski; Merrick I. Ross; April K. Salama; Joseph Skitzki; Jeff Sosman; Susan M. Swetter; Kenneth K. Tanabe; Javier F. Torres-...; Vijay Trisal; Marshall M. Urist; Nicole McMillian; Anita Engh
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Humans; Melanoma; 3. Good health

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.